The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so that's where that I don't want to I don't people to get the impression that if you have an elevated LP little-a you shouldn't be taking a statin now it's quite the opposite you probably should be taking a statin but just understand that the statin is there to control a poby and not LP little-a
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
what's clearly acknowledged is that when you give a patient with elevated LP little a a statin which we do absolutely it's not to lower the LP little a it's to lower the LDL
so your LDL total particle will get down a little bit but part of that is your LP little a particle count but this shows you you are getting benefit when you give a statin to somebody with high yo gr you have to go after residual risk